Targeted Agents in AML (ABT199)

被引：0
|
作者：
Konopleva, Marina [1 ]
DiNardo, Courtney [1 ]
Pan, Rongqing Aaron [1 ]
Han, Lina [1 ]
Zhang, Qi [1 ]
Daver, Naval [1 ]
Kantarjian, Hagop [1 ]
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd 10, Houston, TX 77030 USA
来源：
ANNALS OF HEMATOLOGY | 2017年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S28 / S29
页数：2
相关论文
共 50 条
  • [41] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
    Shundong Cang
    Chaitanya Iragavarapu
    John Savooji
    Yongping Song
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [42] Glycine ameliorates mitochondrial dysfunction caused by ABT-199 in porcine oocytes
    Yu, Sicong
    Gao, Lepeng
    Song, Yang
    Ma, Xin
    Liang, Shuang
    Lan, Hainan
    Zheng, Xin
    Li, Suo
    JOURNAL OF ANIMAL SCIENCE, 2021, 99 (04)
  • [43] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
    Cang, Shundong
    Iragavarapu, Chaitanya
    Savooji, John
    Song, Yongping
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [44] The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132
    Nii, Takenobu
    Ishizawa, Jo
    Prabhu, Varun V.
    Ruvolo, Vivian
    Madhukar, Neel
    Zhao, Ran
    Mu, Hong
    Heese, Lauren
    Kojima, Kensuke
    Garnett, Mathew
    McDermott, Ultan
    Benes, Cyril
    Charter, Neil
    Deacon, Sean
    Elemento, Olivier
    Allen, Joshua
    Oster, Wolfgang
    Stogniew, Martin
    Andreeff, Michael
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Dual Targeting of Ph plus ALL with Dasatinib and ABT-199 (Venetoclax)
    Leonard, Jessica
    Rowley, Joelle
    Hayes-Lattin, Brandon
    Tyner, Jeffrey W.
    Loriaux, Marc
    Druker, Brian J.
    Chang, Bill H.
    BLOOD, 2015, 126 (23)
  • [46] The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
    Touzeau, C.
    Dousset, C.
    Le Gouill, S.
    Sampath, D.
    Leverson, J. D.
    Souers, A. J.
    Maiga, S.
    Bene, M. C.
    Moreau, P.
    Pellat-Deceunynck, C.
    Amiot, M.
    LEUKEMIA, 2014, 28 (01) : 210 - 212
  • [47] The multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis of AML cells both in vitro and in vivo.
    Shankar, DB
    Chang, JC
    Parcells, B
    Sandoval, S
    Li, JL
    Wei, RQ
    Tapang, P
    Davidsen, SK
    Albert, DH
    Glaser, KB
    Moore, TB
    Sakamoto, KM
    BLOOD, 2005, 106 (11) : 183A - 183A
  • [48] Synergistic effects of ABT-199 with conventional chemotherapeutic agents and the CDK inhibitor Dinaciclib in childhood B-cell precursor acute lymphoblastic leukemia
    Seyfried, F.
    Demir, S.
    Hoerl, R.
    Debatin, K. -M.
    Meyer, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 116 - 116
  • [49] Emerging agents and regimens for AML
    Hongtao Liu
    Journal of Hematology & Oncology, 14
  • [50] New agents for AML and MDS
    Grant, Steven
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2009, 22 (04) : 501 - 507
12345